The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.

The combination therapy failed to beat out the company’s other cancer therapy, Opdivo, in patients living with melanomas.

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

After having 17 melanoma spots removed, ‘Real Housewives of Beverly Hills’ alum Teddi Mellencamp was diagnosed with multiple ...

University of Queensland researchers have discovered immunotherapy, when used to treat people with advanced cancers, also ...

University of Queensland researchers have discovered immunotherapy, when used to treat people with advanced cancers, also helps reduce sunspots and skin cancers by at least 65 per cent.

Real Housewives of Beverly Hills star Teddi Mellencamp, 43, was diagnosed 'multiple' brain tumors that may have been caused ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...